Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that a poster on Tonmya (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program.
Tonmya, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. This presents a significant milestone for patients suffering from this chronic pain condition, which has seen limited therapeutic advancements. The data presentation at the AAPM meeting underscores Tonix's commitment to addressing high unmet medical needs in central nervous system (CNS) disorders.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. In addition to Tonmya, the company's CNS commercial infrastructure supports its marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind Tonmya in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Furthermore, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
Beyond CNS, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These initiatives highlight the company's diversified approach to tackling significant medical challenges.
The presentation at the AAPM meeting is crucial as it provides a platform to share clinical data with pain medicine specialists, potentially influencing treatment paradigms for fibromyalgia and other pain conditions. The implications of this announcement extend to patients, healthcare providers, and investors, as positive data could reinforce Tonmya's role in the market and support its expansion into additional indications.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP.
